NAFDAC warns Nigerians on MR.7 SUPER 700000 capsules recall

Nigeria's pharmaceutical sector is facing a critical credibility crisis as regulatory authorities grapple with an expanding wave of counterfeit medications and unverified supplements flooding the market. Recent enforcement actions by the National Agency for Food and Drug Administration and Control (NAFDAC) underscore systemic vulnerabilities that pose both immediate health risks to consumers and significant investment complications for European firms seeking to operate in Africa's largest economy. The simultaneous circulation of counterfeit breast cancer treatment Phesgo 600mg—a critical oncology drug manufactured by Roche—alongside unregulated male enhancement supplements reflects a two-tiered problem afflicting Nigeria's $5.2 billion pharmaceutical market. While these incidents appear disparate on the surface, they reveal a deeper infrastructure challenge: weak supply chain oversight, insufficient border controls, and the prevalence of online distribution channels that circumvent traditional regulatory checkpoints. The Phesgo counterfeit alert represents a particularly acute threat. This biologic drug is essential for HER2-positive breast cancer patients, and counterfeit versions containing sub-therapeutic or toxic ingredients directly compromise patient outcomes while simultaneously undermining trust in legitimate pharmaceutical distribution networks. The fact that counterfeits were identified through Lagos University Teaching Hospital suggests that even institutional healthcare providers lack foolproof authentication mechanisms—a troubling indicator for market maturity. Simultaneously, the proliferation of online-marketed